• Superoxide Dismutase (SOD) Activity Assay Kit: Technical Wor

  2026-06-04

  The Superoxide Dismutase (SOD) Activity Assay Kit (SKU: K2035) enables reliable, quantitative measurement of SOD enzyme activity in biological fluids, addressing the need for reproducible oxidative stress analyses in research. This kit should be used strictly for scientific research and is not suitable for diagnostic or clinical applications.

• Amphotericin B: Mechanistic Insights and Innovations in Fung

  2026-06-04

  Explore the advanced mechanistic landscape of Amphotericin B, a leading polyene antifungal antibiotic, highlighting novel immunomodulatory roles and protocol optimization for fungal infection research. Gain actionable insights distinct from prior articles, with direct application to assay design and translational science.

• Amyloid Beta-peptide (25-35): Workflows for Neurotoxicity Mo

  2026-06-03

  Amyloid Beta-peptide (25-35) (Aβ25-35) empowers highly reproducible Alzheimer's neurotoxicity and microglial polarization assays. Unlock robust experimental workflows, advanced mechanistic insights, and proven troubleshooting strategies for translational neurodegenerative disease research.

• Monoclonal Antibody Blocks CD16a/b Shedding to Boost Tumor A

  2026-06-03

  This study introduces F9H4, a monoclonal antibody that inhibits the cleavage of CD16a and CD16b, enhancing antibody-dependent cellular cytotoxicity (ADCC) against tumors. The findings provide a targeted approach to augment immune cell-mediated tumor clearance without the pleiotropic effects associated with broad protease inhibition.

• MAPK10-Mediated Regulation of KRT16 Suppresses NSCLC Metasta

  2026-06-02

  This study uncovers how MAPK10 suppresses non-small cell lung cancer (NSCLC) metastasis by promoting phosphorylation-dependent ubiquitination and proteasomal degradation of keratin 16 (KRT16). The findings highlight the MAPK10/KRT16/RNF213 axis as a promising therapeutic target and prognostic biomarker in NSCLC, offering new directions for personalized cancer treatment.

• Rotenone as a Mitochondrial Complex I Inhibitor in Disease M

  2026-06-02

  Rotenone is the benchmark mitochondrial Complex I inhibitor for modeling mitochondrial dysfunction, ROS-mediated cell death, and neurodegenerative disease pathways. Its robust application spans from apoptosis and autophagy assays in cell cultures to precise in vivo models, providing researchers with reproducible and translational insights.

• iRhom2 Modulates Olfactory Receptor Regulation and Adaptatio

  2026-06-01

  The reference study uncovers a specialized role for iRhom2 in olfactory sensory neurons, linking odorant receptor activity to dynamic feedback regulation via the iRhom2/ADAM17 pathway. These findings advance our understanding of sensory adaptation mechanisms and inform future molecular assays in neurobiology.

• EPZ-6438: Shaping the Future of Translational EZH2 Inhibitio

  2026-06-01

  This thought-leadership article provides mechanistic insights and strategic guidance on the use of EPZ-6438 in epigenetic cancer research, highlighting its translational value in HPV-associated cervical cancer and beyond. Drawing from recent academic findings and best-practice workflow guides, the article demonstrates how EPZ-6438 empowers researchers to bridge bench-to-bedside gaps in targeting the polycomb repressive complex 2 (PRC2) pathway.

• Deracoxib Modulates Doxorubicin Toxicity in Canine Mammary C

  2026-05-31

  This study systematically explores how the selective COX-2 inhibitor deracoxib influences the cytotoxic and apoptotic effects of doxorubicin on normal canine mammary epithelial cells. The findings point to a reduction in both cell death and nitric oxide production, suggesting a potential strategy for minimizing chemotherapy-induced toxicity in veterinary oncology.

• Cy7 NHS Ester: Practical Guidance for Near-Infrared Labeling

  2026-05-30

  Cy7 NHS ester addresses the need for a highly water-soluble, sulfonated near-infrared dye for sensitive labeling of proteins and peptides, especially those prone to denaturation. It is best suited for workflows requiring direct labeling in aqueous settings and rapid use of dye solutions. It is not recommended for long-term solution storage or strictly organic labeling workflows.

• NLRP10 Supports Keratinocyte Survival and Differentiation in

  2026-05-29

  This study uncovers NLRP10 as a crucial regulator of epidermal homeostasis, demonstrating that its downregulation in atopic dermatitis (AD) impairs keratinocyte survival and differentiation via p63 stabilization. The findings clarify genetic links between NLRP10 and AD, highlighting new therapeutic targets for restoring skin barrier function.

• Amyloid Beta-peptide (25-35): Optimizing Alzheimer’s Disease

  2026-05-29

  Amyloid Beta-peptide (25-35) (Aβ25-35) empowers researchers to build reproducible, mechanistically relevant Alzheimer’s disease neurotoxicity models. This guide translates recent discoveries in microglial polarization and practical workflow enhancements into actionable protocols for reliable neurodegenerative disease research.

• Actinomycin D (SKU A4448): Robust Solutions for Cell Assays

  2026-05-28

  This article delivers practical, scenario-driven insights for scientists leveraging Actinomycin D (SKU A4448) in cell viability, proliferation, and cytotoxicity workflows. Focusing on reproducible apoptosis induction, accurate mRNA stability assays, and vendor selection, we highlight how APExBIO's Actinomycin D advances experimental reliability and data quality.

• FGFR and PI3K/AKT Crosstalk Regulates Periostin in HER2+ Bre

  2026-05-28

  Labrèche et al. provide new mechanistic insight into how periostin expression is regulated in HER2-positive breast cancer cells through FGFR, TGFβ, and PI3K/AKT signaling interplay. Their findings clarify the molecular underpinnings of periostin induction and repression, highlighting therapeutic implications for tumor biology and signaling pathway targeting.

• Z-Ligustilide and Cisplatin Synergy Targets PLPP1 in Lung Ca

  2026-05-27

  This study reveals that combining Z-ligustilide with cisplatin disrupts PLPP1-mediated phospholipid synthesis, sensitizing resistant lung cancer cells to chemotherapy. The findings advance understanding of metabolic vulnerabilities in cisplatin resistance and highlight new targets for improving treatment outcomes.

7921 records 10/529 page Previous Next First page 上5页 678910 下5页 Last page